Ruconest meets Phase III endpoint in BLA-determining trial
This article was originally published in Scrip
Executive Summary
The Phase III trial that Pharming and its US partner Santarus were forced to conduct to progress Ruconest (recombinant human C1 inhibitor) for the treatment of acute attacks of angioedema in patients with hereditary angioedema (HAE) has met its primary endpoint.